Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Opus Genetics, Inc.(IRD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IRD
11/06/2026: IRD (3-star) is currently NOT-A-BUY. Pass it for now.
Opus Genetics is a clinical-stage biotechnology company focused on developing gene therapies for rare inherited retinal diseases. Its core strength lies in a specialized, AAV-based therapeutic pipeline and strong backing from industry-focused venture partners. The primary investment story centers on the potential for its clinical programs, such as OPGx-LCA5, to receive regulatory approval and restore vision for underserved patient populations. Key risks include the high execution uncertainty inherent in clinical trials, significant competitive pressures, and the need for future capital to sustain R&D. The stock is most suitable for growth-oriented investors with a high risk tolerance who are monitoring clinical milestones and regulatory progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-risk, high-reward exposure to breakthrough gene therapy technology. |
| Momentum investor | Mixed fit | Momentum is highly conditional on positive clinical data releases or FDA-related news signals. |
| Value investor | Weak fit | The company lacks stable earnings or cash flow to support traditional value-based valuation models. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on research and development reinvestment. |
| Low-risk investor | Weak fit | Biotechnology clinical-stage stocks exhibit high price volatility and substantial business risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are highly sensitive to trial results and news cycles. |
| Valuation risk | High | Valuations are speculative and depend heavily on future, uncertain clinical outcomes. |
| Competition risk (Gene therapy competition) | Medium / high | Many well-funded firms are competing for similar genetic therapy targets. |
| Business quality | Medium | The business relies on specialized R&D talent and proprietary, yet unproven, therapeutic platforms. |
| Dividend income | Low / none | There is no income component to the stock; it is a purely capital-appreciation-focused investment. |
| Execution risk | High | The ability to successfully navigate complex clinical trials and FDA regulatory pathways is paramount. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 131.37% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 347.76M USD | Price to earnings Ratio - | 1Y Target Price 13.47 |
Price to earnings Ratio - | 1Y Target Price 13.47 | ||
Volume (30-day avg) 1.5M shares | Beta 0.81 | 52 Weeks Range 1.70 - 7.07 | Updated Date 11/08/2026 |
52 Weeks Range 1.70 - 7.07 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Ophthalmic Gene Therapy | Development and future commercialization of AAV-based therapies like OPGx-LCA5 and OPGx-BEST1. | Revenue is currently minimal; the company is a bet on the success of its experimental clinical pipeline. |
Valuation
Trailing PE - | Forward PE 12 | Enterprise Value 294.73M | Price to Sales(TTM) 35.28 |
Enterprise Value 294.73M | Price to Sales(TTM) 35.28 | ||
Enterprise Value to Revenue 29.9 | Enterprise Value to EBITDA -2.55 | Shares Outstanding 83.20M | Shares Floating 65.12M |
Shares Outstanding 83.20M | Shares Floating 65.12M | ||
Percent Insiders 12.12 | Percent Institutions 70.16 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.